Drug Profile
Hemopexin - CSL Behring
Alternative Names: CSL-889; Plasma derived hemopexin therapy - CSL BehringLatest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator CSL Behring
- Class Antianaemics; Beta-globulins
- Mechanism of Action Hemopexin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Sickle cell anaemia
Most Recent Events
- 06 Sep 2023 Phase I development is ongoing in USA (NCT04285827)
- 06 Sep 2023 CSL Behring completes the phase I trial in Sickle cell anaemia (In adults) in United Kingdom, Netherlands and USA (IV) (NCT04285827)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Sickle-cell-anaemia in USA (IV)